In this study, we want to learn whether adding a new oral drug called Venetoclax to standard chemotherapy affects how long children and young adults with acute myeloid leukemia (AML) stay in remission and what side effects they experience.
To evaluate the long-term safety through 15 years post infusion of patients who received IP in a Caribou-sponsored study, special access program or ITT